Testing of the eHealth Pain Education after CANcer (PECAN) program for breast cancer survivors with persistent pain

Feasibility and pilot testing of the eHealth Pain Education after CANcer (PECAN) program for breast cancer survivors with persistent pain: a mixed-method study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN96294982

Enrollment

Registered

2021-10-01

Start date

2021-01-14

Completion date

Unknown

Last updated

2023-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer survivors with persistent pain Signs and Symptoms Other chronic pain

Interventions

After signing informed consent, a baseline assessment (T0) was performed. All outcome measures were self-reported and questioned online. After completing the baseline assessment, participants received

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. History of unilateral axillary lymph node dissection or sentinel node biopsy; mastectomy (with or without autologous reconstruction) or wide excision of the tumour for primary unilateral breast cancer 2. Chemotherapy and radiotherapy finished; hormone and/or immunotherapy finished or ongoing 3. Age >18 years 4. Native Dutch speaking 5. Pain NRS a minimum of 3/10 during the past week

Exclusion criteria

Exclusion criteria: 1. Adolescents 2. Breast cancer patients were surgery/chemotherpy/radiotherapy are still ungoing 3. NRS below 3/10 during the past week 4. No native Dutch speaker

Design outcomes

Primary

Measure	Time frame
1. Acceptability, comprehensibility, and satisfaction were measured quantitatively with a self-constructed questionnaire and described qualitatively using focus groups at 6 weeks (T1) 2. Pain Disability Index for pain-related disability at baseline (T0), after 6 weeks (T1) and 3 months (T2)	—

Secondary

Measure	Time frame
1. Pain symptoms and characteristics measured using the Numeric Rating Scale for pain intensity, the Brief pain inventory (pain severity and pain interference) , the Self-administered Leeds Assessment of Neuropathic Symptoms and Signs and the Central Sensitisation Inventory 2. Physical function measured using the PROMIS physical function short form 3. Emotional functioning measure using the Pain Catastrophizing Scale, the Depression Anxiety Stress scales 21, the Bodily Threat Monitoring Scale and the McGill Quality of Life Questionnaire 4. Self-efficacy measures using the Pain self-efficacy questionnaire All self-reported outcome measures were collected at baseline (T0), after 6 weeks (T1) and 3 months (T2) to estimate the change form baseline.	—

Measure

Time frame

1. Pain symptoms and characteristics measured using the Numeric Rating Scale for pain intensity, the Brief pain inventory (pain severity and pain interference) , the Self-administered Leeds Assessment of Neuropathic Symptoms and Signs and the Central Sensitisation Inventory 2. Physical function measured using the PROMIS physical function short form 3. Emotional functioning measure using the Pain Catastrophizing Scale, the Depression Anxiety Stress scales 21, the Bodily Threat Monitoring Scale and the McGill Quality of Life Questionnaire 4. Self-efficacy measures using the Pain self-efficacy questionnaire All self-reported outcome measures were collected at baseline (T0), after 6 weeks (T1) and 3 months (T2) to estimate the change form baseline.

—

Countries

Belgium

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026